Overview

Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225.
Phase:
Phase 1
Details
Lead Sponsor:
Laboratoires Thea
Treatments:
Azithromycin